A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity

Korábbi kezelés

• Have had any of the following heart conditions within 6 months prior to screening:
  • heart attack
  • stroke
  • hospitalization due to heart failure
• Have a self-reported change in body weight greater than 5 kilograms (kg) (11 pounds) within 3 months prior to screening
• Have a prior or planned surgical treatment for obesity
• Have had any of the following heart conditions within 6 months prior to screening:
  • heart attack
  • stroke
  • hospitalization due to heart failure
• Have taken any medications or alternative remedies for weight loss within 3 months prior to screening

Más betegség

• Participants with Type 2 Diabetes:
• Have type 1 diabetes
• Have New York Heart Association Functional Classification Class III or IV congestive heart failure (CHF)
• Have type 2 diabetes along with morbid obesity and being considered for bariatric surgery or any other procedure intended for weight loss
  • Participants with Obesity or Overweight without Type 2 Diabetes:
• Have type 1 diabetes or type 2 diabetes
• Have New York Heart Association Functional Classification Class III or IV CHF

• Participants with Type 2 Diabetes:
• Have had type 2 diabetes for at least one year
• Insulin naive
• Have HbA1c ≥7.5% and ≤10% at screening
• Have body mass index (BMI) ≥23 kilograms per square meter (kg/m2)
  • Participants with Obesity or Overweight without Type 2 Diabetes:
• Have a BMI
  • Greater than or equal to 30 kg/m2 OR
  • Greater than or equal to 27 kg/m2 AND previously diagnosed with at least one of the following weight-related comorbidities: high blood pressure, lipid disorder, obstructive sleep apnea, heart disease